Intractable complicated course of tricuspid valve infective endocarditis due to non-compliance of treatment with clinical guidelines with a decisive role of molecular biological study in etiological diagnosis: a case report

A clinical observation of the treatment non-compliance consequences with clinical guidelines and principles of empirical therapy selection in a female patient with intravenous drug abuse, viral hepatitis C and HIV infection, with a history of a COVID-19 and the development of uncontrolled staphylococcal infective endocarditis (IE) of the tricuspid valve, complicated recurrence of early prosthetic IE is presented. Successful treatment was achieved only by a combination of tricuspid valve replacement and the appointment of etiotropic therapy for S. aureus (MSSA). The typical clinical scenario was not accompanied by the choice of adequate empirical antibiotic therapy, despite the high suspicion of association with MSSA, which determined the complicated course of IE. Only the polymerase chain reaction of the heart valve tissue played a key role in the etiological diagnosis. The use of valve tissue polymerase chain reaction in addition to traditional microbiological methods is a valuable diagnostic study.

1. Habib G, Lancellotti P, Antunes MJ, et al.; ESC Scientific Document Group. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075-3128. DOI:10.1093/eurheartj/ehv319.

2. Kumanayaka D, Mutyala M, Reddy DV, Slim J. Coronavirus Disease 2019 Infection as a Risk Factor for Infective Endocarditis. Cureus. 2021;13(5):e14813. DOI:10.7759/cureus.14813.

3. Kaka AS, Filice GA, Kuskowski M, Musher DM. Does active hepatitis C virus infection increase the risk for infection due to Staphylococcus aureus? Eur J Clin Microbiol Infect Dis. 2017;36(7):1217-1223. DOI:10.1007/s10096-017-2912-0.

4. Demin AA, Kobalava ZD, Skopin II, et al. Infectious endocarditis and infection of intracardiac devices in adults. Clinical guidelines 2021. Russian Journal of Cardiology. 2022;27(10):5233. (in Russ.) DOI:10.15829/1560-4071-2022-5233.

5. Kotova EO, Domonova EA, Kobalava ZhD, et al. Modern trends in identification of causative agents in infective endocarditis. Rational Pharmacotherapy in Cardiology. 2021;17(1):153-164 (In Russ.) DOI:10.20996/1819-6446-2021-02-14.

6. Tissot-Dupont H, Casalta JP, Gouriet F, et al. International experts’ practice in the antibiotic therapy of infective endocarditis is not following the gui delines. Clinical Microbiology and Infection. 2017;23:736-739. DOI:10.1016/j.cmi.2017.03.007.

7. Danilov AI, Alekseeva IV, Asner TV, et al. Real practice of therapy of infective endocarditis in the Russian Federation: intermediate results of the MAESTRO study. Clinical Microbiology and Antimicrobial Chemotherapy. 2013;15(2);suppl 1:18-9 (In Russ.)

8. Scheggi V, Del Pace S, Ceschia N, et al. Infective endocarditis in intravenous drug abusers: clinical challenges emerging from a single-centre experience. BMC Infect Dis. 2021;21(1):1010. DOI:10.1186/s12879-021-06697-1.

9. Fournier PE, Gouriet F, Casalta JP, et al. Blood culture-negative endocarditis: Improving the diagnostic yield using new diagnostic tools. Medicine (Baltimore). 2017;96(47):e8392. DOI:10.1097/MD.0000000000008392.

10. Halavaara M, Martelius T, Anttila VJ, Järvinen A. Three Separate Clinical Entities of Infective Endocarditis-A Population-Based Study From Southern Finland 20132017. Open Forum Infect Dis. 2020;7(9):ofaa334. DOI:10.1093/ofid/ofaa334.

11. Zubarevich A, Szczechowicz M, Osswald A, et al. Surgical treatment of infective endocarditis in intravenous drug abusers. J Cardiothorac Surg. 2021;16(1):97. DOI:10.1186/s13019-021-01491-1.

12. Pericàs JM, Llopis J, Athan E, et al. Prospective Cohort Study of Infective Endocarditis in People Who Inject Drugs. J Am Coll Cardiol. 2021;77(5):544-555. DOI:10.1016/j.jacc.2020.11.062.

13. Zeng X, McMahon GM, Brunelli SM, et al. Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. Clin J Am Soc Nephrol. 2014;9(1):12-20. DOI:10.2215/CJN.02730313.

14. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and mana gement of pericardial diseases. Russian Journal of Cardiology. 2016;(5): 117-162. (In Russ.) DOI:10.15829/15604071-2016-5-117-162.